Cancer

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and…

3 weeks ago

Teams Announced for the 2024 StaffDNA® Cure Bowl

PLANO, Texas, Dec. 9, 2024 /PRNewswire/ -- ESPN Events along with the Orlando Sports Foundation (OSF) announced that Jacksonville State…

3 weeks ago

Moonpig and St. Jude’s Children’s Research Hospital Team Up To Spread Holiday Cheer to Those in Need

The online custom card company pledges to donate $5 for every card purchased to support St. Jude with a specially…

3 weeks ago

Carta Healthcare to Power Oncology Research and Clinical Trials with Acquisition of Realyze Intelligence, a UPMC Enterprises Company

Clinician-trained AI analyzes electronic records to match ideal patients with studies in seconds rather than hours, optimizing research and reducing…

3 weeks ago

Theralase(R) Launches Three New Clinical Study Sites in USA

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites…

3 weeks ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

3 weeks ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release…

3 weeks ago